# Orasure Technologies Inc: financial statements, quarterly

OSUR · Nasdaq · CIK 1116463 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/osur.md) · [Financials](/companies/osur/financials.md) · [Filings](/companies/osur/filings.md) · [Insiders](/companies/osur/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/osur/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [89.2](/filings/0001116463-24-000049.md) | [75.9 d](/filings/0001116463-26-000016.md) | [54.1](/filings/0001116463-25-000038.md) | [54.3](/filings/0001628280-25-038379.md) | [39.9](/filings/0001116463-25-000054.md) | [37.4 d](/filings/0001116463-26-000016.md) | [29.9](/filings/0001116463-26-000041.md) | [31.2](/filings/0001116463-26-000052.md) | [27.1](/filings/0001116463-25-000054.md) | [26.8 d](/filings/0001116463-26-000016.md) | [27.9](/filings/0001116463-26-000041.md) | [30.6](/filings/0001116463-26-000052.md) |
| Cost of revenue | $m | [44.8](/filings/0001116463-24-000049.md) | [40.8 d](/filings/0001116463-26-000016.md) | [30.1](/filings/0001116463-25-000038.md) | [29.6](/filings/0001628280-25-038379.md) | [22.8](/filings/0001116463-25-000054.md) | [23.9 d](/filings/0001116463-26-000016.md) | [17.6](/filings/0001116463-26-000041.md) | [18.1](/filings/0001116463-26-000052.md) | [15.3](/filings/0001116463-25-000054.md) | [15.8 d](/filings/0001116463-26-000016.md) | [16.1](/filings/0001116463-26-000041.md) | [17.3](/filings/0001116463-26-000052.md) |
| Gross profit | $m | [44.3](/filings/0001116463-24-000049.md) | [35.1 d](/filings/0001116463-26-000016.md) | [24.1](/filings/0001116463-25-000038.md) | [24.7](/filings/0001628280-25-038379.md) | [17.1](/filings/0001116463-25-000054.md) | [13.6 d](/filings/0001116463-26-000016.md) | [12.3](/filings/0001116463-26-000041.md) | [13.2](/filings/0001116463-26-000052.md) | [11.8](/filings/0001116463-25-000054.md) | [11.0 d](/filings/0001116463-26-000016.md) | [11.8](/filings/0001116463-26-000041.md) | [13.3](/filings/0001116463-26-000052.md) |
| Research and development | $m | [8.5](/filings/0001116463-24-000049.md) | [7.0 d](/filings/0001116463-26-000016.md) | [7.7](/filings/0001116463-25-000038.md) | [6.6](/filings/0001628280-25-038379.md) | [5.6](/filings/0001116463-25-000054.md) | [6.1 d](/filings/0001116463-26-000016.md) | [9.6](/filings/0001116463-26-000041.md) | [11.4](/filings/0001116463-26-000052.md) | [10.1](/filings/0001116463-25-000054.md) | [11.4 d](/filings/0001116463-26-000016.md) | [13.7](/filings/0001116463-26-000041.md) | [9.4](/filings/0001116463-26-000052.md) |
| Operating income | $m | [10.9](/filings/0001116463-24-000049.md) | [3.9 d](/filings/0001116463-26-000016.md) | [(7.1)](/filings/0001116463-25-000038.md) | [(2.7)](/filings/0001628280-25-038379.md) | [(6.0)](/filings/0001116463-25-000054.md) | [(12.4) d](/filings/0001116463-26-000016.md) | [(17.8)](/filings/0001116463-26-000041.md) | [(18.0)](/filings/0001116463-26-000052.md) | [(16.1)](/filings/0001116463-25-000054.md) | [(20.1) d](/filings/0001116463-26-000016.md) | [(23.3)](/filings/0001116463-26-000041.md) | [5.4](/filings/0001116463-26-000052.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [2.3](/filings/0001116463-24-000049.md) | [0.6 d](/filings/0001116463-26-000016.md) | [(0.0)](/filings/0001116463-25-000038.md) | [0.4](/filings/0001628280-25-038379.md) | [0.7](/filings/0001116463-25-000054.md) | [0.8 d](/filings/0001116463-26-000016.md) | [(0.5)](/filings/0001116463-26-000041.md) | [2.0](/filings/0001116463-26-000052.md) | [0.0](/filings/0001116463-25-000054.md) | [0.2 d](/filings/0001116463-26-000016.md) | [(0.4)](/filings/0001116463-26-000041.md) | [0.1](/filings/0001116463-26-000052.md) |
| Net income | $m | [11.2](/filings/0001116463-24-000049.md) | [20.1 d](/filings/0001116463-26-000016.md) | [(3.6)](/filings/0001116463-25-000054.md) | [(0.6)](/filings/0001116463-25-000054.md) | [(4.5)](/filings/0001116463-25-000054.md) | [(10.8) d](/filings/0001116463-26-000016.md) | [(16.0)](/filings/0001116463-26-000052.md) | [(19.7)](/filings/0001116463-26-000052.md) | [(13.7)](/filings/0001116463-25-000054.md) | [(19.3) d](/filings/0001116463-26-000016.md) | [(22.4)](/filings/0001116463-26-000052.md) | [6.2](/filings/0001116463-26-000052.md) |
| Diluted EPS | $ per share | [0.15](/filings/0001116463-24-000049.md) | not reported | [(0.05)](/filings/0001116463-25-000038.md) | [(0.01)](/filings/0001628280-25-038379.md) | [(0.06)](/filings/0001116463-25-000054.md) | not reported | [(0.21)](/filings/0001116463-26-000041.md) | [(0.26)](/filings/0001116463-26-000052.md) | [(0.19)](/filings/0001116463-25-000054.md) | not reported | [(0.32)](/filings/0001116463-26-000041.md) | [0.09](/filings/0001116463-26-000052.md) |
| Basic EPS | $ per share | [0.15](/filings/0001116463-24-000049.md) | not reported | [(0.05)](/filings/0001116463-25-000038.md) | [(0.01)](/filings/0001628280-25-038379.md) | [(0.06)](/filings/0001116463-25-000054.md) | not reported | [(0.21)](/filings/0001116463-26-000041.md) | [(0.26)](/filings/0001116463-26-000052.md) | [(0.19)](/filings/0001116463-25-000054.md) | not reported | [(0.32)](/filings/0001116463-26-000041.md) | [0.09](/filings/0001116463-26-000052.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [218](/filings/0001116463-23-000024.md) | [290](/filings/0001116463-25-000010.md) | [247](/filings/0001628280-24-022250.md) | [258](/filings/0001116463-24-000036.md) | [279](/filings/0001116463-24-000049.md) | [268](/filings/0001116463-26-000016.md) | [248](/filings/0001116463-25-000038.md) | [235](/filings/0001628280-25-038379.md) | [216](/filings/0001116463-25-000054.md) | [199](/filings/0001116463-26-000052.md) | [177](/filings/0001116463-26-000041.md) | [161](/filings/0001116463-26-000052.md) |
| Current assets | $m | [356](/filings/0001116463-23-000024.md) | [386](/filings/0001116463-25-000010.md) | [349](/filings/0001628280-24-022250.md) | [351](/filings/0001116463-24-000036.md) | [350](/filings/0001116463-24-000049.md) | [333](/filings/0001116463-26-000016.md) | [314](/filings/0001116463-25-000038.md) | [301](/filings/0001628280-25-038379.md) | [283](/filings/0001116463-25-000054.md) | [262](/filings/0001116463-26-000052.md) | [241](/filings/0001116463-26-000041.md) | [223](/filings/0001116463-26-000052.md) |
| Total assets | $m | [458](/filings/0001116463-23-000024.md) | [483](/filings/0001116463-25-000010.md) | [468](/filings/0001628280-24-022250.md) | [466](/filings/0001116463-24-000036.md) | [464](/filings/0001116463-24-000049.md) | [480](/filings/0001116463-26-000016.md) | [458](/filings/0001116463-25-000038.md) | [445](/filings/0001628280-25-038379.md) | [423](/filings/0001116463-25-000054.md) | [403](/filings/0001116463-26-000052.md) | [379](/filings/0001116463-26-000041.md) | [361](/filings/0001116463-26-000052.md) |
| Current liabilities | $m | [40.9](/filings/0001116463-23-000024.md) | [39.5](/filings/0001116463-25-000010.md) | [29.1](/filings/0001628280-24-022250.md) | [28.9](/filings/0001116463-24-000036.md) | [27.8](/filings/0001116463-24-000049.md) | [33.5](/filings/0001116463-26-000016.md) | [25.4](/filings/0001116463-25-000038.md) | [42.4](/filings/0001628280-25-038379.md) | [40.2](/filings/0001116463-25-000054.md) | [39.8](/filings/0001116463-26-000052.md) | [44.1](/filings/0001116463-26-000041.md) | [25.1](/filings/0001116463-26-000052.md) |
| Total liabilities | $m | [53.5](/filings/0001116463-23-000024.md) | [52.2](/filings/0001116463-25-000010.md) | [41.3](/filings/0001628280-24-022250.md) | [40.5](/filings/0001116463-24-000036.md) | [38.5](/filings/0001116463-24-000049.md) | [69.3](/filings/0001116463-26-000016.md) | [61.3](/filings/0001116463-25-000038.md) | [64.3](/filings/0001628280-25-038379.md) | [61.1](/filings/0001116463-25-000054.md) | [62.3](/filings/0001116463-26-000052.md) | [65.8](/filings/0001116463-26-000041.md) | [42.8](/filings/0001116463-26-000052.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [405](/filings/0001116463-24-000049.md) | [431](/filings/0001116463-26-000016.md) | [426](/filings/0001116463-25-000054.md) | [426](/filings/0001116463-25-000054.md) | [426](/filings/0001116463-25-000054.md) | [410](/filings/0001116463-26-000052.md) | [396](/filings/0001116463-26-000052.md) | [381](/filings/0001116463-26-000052.md) | [362](/filings/0001116463-25-000054.md) | [341](/filings/0001116463-26-000052.md) | [313](/filings/0001116463-26-000052.md) | [318](/filings/0001116463-26-000052.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [36.9 d](/filings/0001116463-24-000049.md) | [41.4 d](/filings/0001116463-26-000016.md) | [6.7](/filings/0001116463-25-000038.md) | [7.8 d](/filings/0001628280-25-038379.md) | [12.7 d](/filings/0001116463-25-000054.md) | [0.1 d](/filings/0001116463-26-000016.md) | [(19.7)](/filings/0001116463-26-000041.md) | [(10.2) d](/filings/0001116463-26-000052.md) | [(10.1) d](/filings/0001116463-25-000054.md) | [(9.0) d](/filings/0001116463-26-000016.md) | [(13.9)](/filings/0001116463-26-000041.md) | [(9.9) d](/filings/0001116463-26-000052.md) |
| Capital expenditure | $m | [1.6 d](/filings/0001116463-24-000049.md) | [1.3 d](/filings/0001116463-26-000016.md) | [1.6](/filings/0001116463-25-000038.md) | [1.6 d](/filings/0001628280-25-038379.md) | [0.1 d](/filings/0001116463-25-000054.md) | [0.5 d](/filings/0001116463-26-000016.md) | [0.4](/filings/0001116463-26-000041.md) | [1.9 d](/filings/0001116463-26-000052.md) | [0.9 d](/filings/0001116463-25-000054.md) | [0.9 d](/filings/0001116463-26-000016.md) | [0.9](/filings/0001116463-26-000041.md) | [2.4 d](/filings/0001116463-26-000052.md) |
| Share repurchases | $m | [0.2 d](/filings/0001116463-24-000049.md) | [(1.9) d](/filings/0001116463-26-000016.md) | [1.5](/filings/0001116463-25-000038.md) | [(1.5) d](/filings/0001628280-25-038379.md) | [0.0 d](/filings/0001116463-25-000054.md) | [0.0 d](/filings/0001116463-26-000016.md) | [0.0](/filings/0001116463-26-000041.md) | [5.0 d](/filings/0001116463-26-000052.md) | [5.0 d](/filings/0001116463-25-000054.md) | [5.0 d](/filings/0001116463-26-000016.md) | [5.0](/filings/0001116463-26-000041.md) | [2.0 d](/filings/0001116463-26-000052.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [72.8](/filings/0001116463-23-000024.md) | [74.0](/filings/0001628280-24-022250.md) | [73.3](/filings/0001116463-24-000036.md) | [74.3](/filings/0001116463-24-000049.md) | [73.9](/filings/0001116463-25-000038.md) | [74.2](/filings/0001628280-25-038379.md) | [74.6](/filings/0001116463-25-000054.md) | [74.9](/filings/0001116463-26-000041.md) | [74.5](/filings/0001116463-26-000052.md) | [73.0](/filings/0001116463-25-000054.md) | [69.7](/filings/0001116463-26-000041.md) | [70.2](/filings/0001116463-26-000052.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 68,968,627 at 2026-07-31, from the cover of the [10-Q filed 2026-08-07](/filings/0001116463-26-000052.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.